Swedish study reports low vision loss risk with GLP-1RAs
1. In this cohort study, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a higher risk of anterior ischemic ...
Tag: glucagon-like peptide-1 (GLP-1) receptor agonists
GLP-1RAs may increase ischemic optic neuropathy risk
1. In this target trial emulation, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a small increase in the ...
GLP-1RAs showed no advantage for basal insulin discontinuation
1. In this target trial emulation, initiating a glucagon-like peptide-1 receptor agonist (GLP-1RA) was not associated with higher rates of ...
Glucagon-like peptide-1 receptor agonists are associated with reduced risk of developing substance use disorders
1. Use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced risk of developing substance use disorders among US ...
Semaglutide and tirzepatide may be cost-effective for knee osteoarthritis in patients with obesity
1. In this microsimulation model, the two glucagon-like peptide-1 receptor agonists were shown to be cost-effective when added to usual ...
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors associated with similar dementia risk in older adults
1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) did not significantly affect the risk of dementia ...
Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
1. In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher ...
Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
1. In this post-hoc analysis of the SURMOUNT-1 trial, there was a mostly linear relationship between percentage change in weight ...
Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes
1. In this retrospective cohort study, treatment with semaglutide resulted in nominally lower incidence of the composite of death, myocardial ...
Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
